Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial

European Journal of Cancer

Volumn 49, Issue 16, 2013, Pages 3431-3441

  Trovik, Jone ^a,b   Wik, Elisabeth ^a,b   Werner, Henrica M J ^a,b   Krakstad, Camilla ^b   Helland, Harald ^a   Vandenput, Ingrid ^c   Njolstad, Tormund S ^b   Stefansson, Ingunn M ^a,b   Marcickiewicz, Janusz ^d,e   Tingulstad, Solveig ^f   Staff, Anne C ^g   Amant, Frederic ^c   Akslen, Lars A ^a,b   Salvesen, Helga B ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e Department of Medicine   (Sweden)

^f TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^g ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Biomarker; Curettage; Endometrial cancer; Hormone receptors; Lymph node metastases; Prognosis

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; ENDOMETRIUM BIOPSY; ENDOMETRIUM CARCINOMA; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BIOMARKER; CURETTAGE; ENDOMETRIAL CANCER; HORMONE RECEPTORS; LYMPH NODE METASTASES; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CARCINOMA; CHI-SQUARE DISTRIBUTION; DILATATION AND CURETTAGE; DISEASE-FREE SURVIVAL; DOWN-REGULATION; ENDOMETRIAL NEOPLASMS; EUROPE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84885183578     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.06.016     Document Type: Article

References (43)

1. C.P. Morrow, B.N. Bundy, and R.J. Kurman Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study Gynecol Oncol 40 1 1991 55 65
2. V.M. Abeler, and K.E. Kjorstad Endometrial adenocarcinoma in Norway. A study of a total population Cancer 67 12 1991 3093 3103
3. F. Bray Cancer in Norway 2008 report 2009 Cancer Registry of Norway Oslo
4. EBCTCG EBCTCG Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 9472 2005 1687 1717
5. H.R. Chang Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer Cancer 116 12 2010 2856 2867
6. K.J. Dedes, D. Wetterskog, A. Ashworth, S.B. Kaye, and J.S. Reis-Filho Emerging therapeutic targets in endometrial cancer Nat Rev Clin Oncol 8 5 2011 261 271
7. H.B. Salvesen, S.L. Carter, and M. Mannelqvist Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation Proc Natl Acad Sci U S A 106 12 2009 4834 4839
8. H.B. Salvesen, I.S. Haldorsen, and J. Trovik Markers for individualised therapy in endometrial carcinoma Lancet Oncol 13 8 2012 e353 e361
9. A. Mariani, S.C. Dowdy, G.L. Keeney, H.J. Long, T.G. Lesnick, and K.C. Podratz High-risk endometrial cancer subgroups: candidates for target-based adjuvant therapy Gynecol Oncol 95 1 2004 120 126
10. H. Kitchener, A. Swart, Q. Qian, C. Amos, and M. Parmar Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study Lancet 373 9658 2009 125 136
11. P. Panici Benedetti, S. Basile, and F. Maneschi Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial J Natl Cancer Inst 100 23 2008 1707 1716
12. F. Amant, P. Moerman, P. Neven, D. Timmerman, E. Van Limbergen, and I. Vergote Endometrial cancer Lancet 366 9484 2005 491 505
13. H.M. Werner, J. Trovik, and J. Marcickiewicz A discordant histological risk classification in preoperative and operative biopsy in endometrial cancer is reflected in metastatic risk and prognosis Eur J Cancer 49 3 2013 625 632
14. J.V. Bokhman Two pathogenetic types of endometrial carcinoma Gynecol Oncol 15 1 1983 10 17
15. Y. Todo, H. Kato, M. Kaneuchi, H. Watari, M. Takeda, and N. Sakuragi Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis Lancet 375 9721 2010 1165 1172
16. S. Pecorelli Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium Int J Gynaecol Obstet 105 2 2009 103 104
17. W.T. Creasman The current status of lymphadenectomy in the management of endometrial cancer Womens Health (Lond Engl) 7 1 2011 33 35
18. ClinicalTrials.gov. Molecular Markers in Treatment in Endometrial Cancer, NCT00598845. Bethesda: U.S. National Institutes of Health.
19. Tavasolli FA, Devillee P. (Eds.). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. IARC Press: Lyon, France; 2003. p. 217-232.
20. I.B. Engelsen, I.M. Stefansson, L.A. Akslen, and H.B. Salvesen GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival Am J Obstet Gynecol 199 5 2008 543.e1-7
21. J. Kononen, L. Bubendorf, and A. Kallioniemi Tissue microarrays for high-throughput molecular profiling of tumor specimens Nat Med 4 7 1998 844 847
22. T. Aas, A.L. Borresen, and S. Geisler Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients Nat Med 2 7 1996 811 814
23. H.B. Salvesen, O.E. Iversen, and L.A. Akslen Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study J Clin Oncol 17 5 1999 1382 1390
24. I.B. Engelsen, I. Stefansson, L.A. Akslen, and H.B. Salvesen Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas Am J Obstet Gynecol 195 4 2006 979 986
25. J. Trovik, E. Wik, and I.M. Stefansson Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer Clin Cancer Res 17 10 2011 3368 3377
26. E. von Elm, D.G. Altman, M. Egger, S.J. Pocock, P.C. Gotzsche, and J.P. Vandenbroucke The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies J Clin Epidemiol 61 4 2008 344 349
27. L.M. McShane, D.G. Altman, W. Sauerbrei, S.E. Taube, M. Gion, and G.M. Clark REporting recommendations for tumor MARKer prognostic studies (REMARK) Nat Clin Pract Oncol 2 8 2005 416 422
28. K. May, A. Bryant, H.O. Dickinson, S. Kehoe, and J. Morrison Lymphadenectomy for the management of endometrial cancer Cochrane Database Syst Rev 1 2010 CD007585
29. K.M. Greven, R.M. Lanciano, B. Corn, D. Case, and M.E. Randall Pathologic stage III endometrial carcinoma. Prognostic factors and patterns of recurrence Cancer 71 11 1993 3697 3702
30. J. Marcickiewicz, and K. Sundfeldt Accuracy of intraoperative gross visual assessment of myometrial invasion in endometrial cancer Acta Obstet Gynecol Scand 90 8 2011 846 851
31. L. Savelli, M. Ceccarini, and M. Ludovisi Preoperative local staging of endometrial cancer: transvaginal sonography vs. magnetic resonance imaging Ultrasound Obstet Gynecol 31 5 2008 560 566
32. I.S. Haldorsen, and H.B. Salvesen Staging of endometrial carcinomas with MRI using traditional and novel MRI techniques Clin Radiol 67 1 2012 2 12
33. X. Wang, H. Zhang, W. Di, and W. Li Clinical factors affecting the diagnostic accuracy of assessing dilation and curettage vs frozen section specimens for histologic grade and depth of myometrial invasion in endometrial carcinoma Am J Obstet Gynecol 201 2 2009 194.e1 194.e10
34. B. Lampe, R. Kurzl, and P. Hantschmann Reliability of tumor typing of endometrial carcinoma in prehysterectomy curettage Int J Gynecol Pathol 14 1 1995 2 6
35. M. Frumovitz, D.K. Singh, and L. Meyer Predictors of final histology in patients with endometrial cancer Gynecol Oncol 95 3 2004 463 468
36. H.M. Werner, J. Trovik, and J. Marcickiewicz A discordant histological risk classification in preoperative and operative biopsy in endometrial cancer is reflected in metastatic risk and prognosis Eur J Cancer 49 3 2013 625 632
37. I.B. Engelsen, L.A. Akslen, and H.B. Salvesen Biologic markers in endometrial cancer treatment APMIS 117 10 2009 693 707
38. A. Mariani, T.J. Sebo, and J.A. Katzmann Endometrial cancer: can nodal status be predicted with curettage? Gynecol Oncol 96 3 2005 594 600
39. D. Zhang, M. Salto-Tellez, T.C. Putti, E. Do, and E.S. Koay Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer Mod Pathol 16 1 2003 79 84
40. B.G. Haffty, Q. Yang, and M. Reiss Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer J Clin Oncol 24 36 2006 5652 5657
41. E. Wik, M.B. Raeder, and C. Krakstad Lack of Estrogen receptor alpha is associated with epithelial-mesenchymal transition and PI3Kinase alterations in endometrial carcinoma Clin Cancer Res 19 5 2013 1094 1105
42. F. Kokka, E. Brockbank, D. Oram, C. Gallagher, and A. Bryant Hormonal therapy in advanced or recurrent endometrial cancer Cochrane Database Syst Rev 12 2010 CD007926
43. J.K. Chan, A.E. Sherman, and D.S. Kapp Influence of gynecologic oncologists on the survival of patients with endometrial cancer J Clin Oncol 29 7 2011 832 838